WASHINGTON, D.C.—It is no small task to summarize an entire year’s worth of research accomplishments in any field of medicine, let alone one as complex as rheumatology. At ACR Convergence 2024, the Pediatric Year in Review not only provided a thoughtful summary, but also grouped advances along several different themes. Immune Health & More Jessica…
Dr. Khaled Elsaid discussed synovial macrophages/monocytes and monosodium urate crystal interactions at a session during ACR Convergence, exploring potential new gout pharmacology targets via the lubricin/CD44/protein phosphatase 2A (PP2A) pathway.
Magdalena “Maggie” Cadet, MD, a rheumatologist in New York City, remembers learning about the relationship between physical activity and bone health at a young age. She was 5 years old when she first began taking ballet, jazz and tap-dancing lessons. At 9, she became a competitive figure skater and practiced both dance and ice skating…
Howard Schubiner, MD, shares what led him to focus on the mind-body connection during an episode of the ACR on Air podcast. He discusses recent research into how pain reprocessing may help patients suffering from psychological-related chronic pain.
Through a project to reduce gaps and inequities in lupus care and treatment, ACR work groups have developed five quality measures focused on clinical and patient-reported outcomes and are integrating them into the RISE registry to support patient care and research.
A minority of patients with polymyalgia rheumatica (PMR) who were new to rheumatology practice were prescribed steroid-sparing agents through two years of follow-up. This is according to a large, U.S.-based cohort study, published in Arthritis Care & Research, which also found that nearly two-thirds of the patients remained on glucocorticoids beyond one year.1 “Our study…
At ACR Convergence 2023, experts addressed important topics in gout research, including treating and preventing gout flares, lowering urate levels and managing comorbidities, as well as racial inequities in gout treatment, disease burden and outcomes.
I was cleaning out an old storage closet in my parents’ house in Florida when I stumbled across some notes I took in medical school. As I leafed through pages and pages of notes filled with doodles and reminders, I found a statement that gave me pause: “Immunology—what is it good for?!” To be honest,…
Disparities, representativeness, algorithmic bias, the disruptive emergence of large language models and continued misinformation spread are key issues poised to transform patient care in American healthcare, FDA Commissioner Robert M. Califf, MD, said during a recent event.
The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) based on a short-term study that demonstrated improved pain, function and other symptoms of nr-axSpA in patients with active disease.